![]() RespireRx believes, subject to meeting with the Food and Drug Administration (“FDA”), that dronabinol is Phase 3 ready. RespireRx is developing dronabinol for Obstructive Sleep Apnea (“OSA”), a condition that affects an estimated 29.4 million Americans and for which there is no approved pharmaceutical therapy. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on September 4, 2018, it entered into a dronabinol Development and Supply Agreement (“Agreement”) with Noramco, Inc. 10, 2018 (GLOBE NEWSWIRE) - Septem/Globe Newswire – RespireRx Pharmaceuticals Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |